Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZyVersa Therapeutics Inc. (ZVSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: ZVSA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -86.24% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.58M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 301774 | Beta 0.47 | 52 Weeks Range 0.58 - 8.05 | Updated Date 04/1/2025 |
52 Weeks Range 0.58 - 8.05 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 491.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.74% | Return on Equity (TTM) -96.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1569930 | Price to Sales(TTM) - |
Enterprise Value -1569930 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.21 | Shares Outstanding 2508180 | Shares Floating 2561719 |
Shares Outstanding 2508180 | Shares Floating 2561719 | ||
Percent Insiders 0.24 | Percent Institutions 3.16 |
Analyst Ratings
Rating 5 | Target Price 20 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ZyVersa Therapeutics Inc.
Company Overview
History and Background
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class drugs for inflammatory and fibrotic diseases. Founded to address unmet medical needs, they are developing products based on their inflammasome ASC inhibitor, and a cholesterol efflux mediator.
Core Business Areas
- Inflammasome ASC Inhibitor Program: Developing inflammasome ASC inhibitor for inflammatory diseases, with emphasis on renal and metabolic conditions.
- Cholesterol Efflux Mediator Program: Developing a cholesterol efflux mediator for the treatment of atherosclerotic cardiovascular disease.
Leadership and Structure
The leadership team comprises experienced executives and scientists in drug development. The structure includes a board of directors and management team overseeing research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- VAR 200: VAR200 is a cholesterol efflux mediator currently in preclinical development for atherosclerotic cardiovascular disease. Market share data is currently unavailable as it is still in preclinical development. Competitors include companies developing similar therapies targeting cholesterol metabolism like Novartis (Leqvio) and Amgen (Repatha).
- IC 100: IC 100 is an inflammasome ASC inhibitor under development for inflammatory diseases such as diabetic kidney disease. Market share data is currently unavailable as it is still in clinical development. Competitors include companies developing anti-inflammatory therapies like Pfizer (JAK inhibitors) and Novartis (IL-1beta inhibitors).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, driven by innovation and regulatory approvals. Inflammatory and fibrotic diseases, and cardiovascular diseases represent significant markets with unmet needs.
Positioning
ZyVersa Therapeutics Inc. positions itself as a leader in developing first-in-class drugs for inflammatory and fibrotic diseases, with focus on inflammasome ASC inhibition and cholesterol efflux mediation.
Total Addressable Market (TAM)
The total addressable market for therapies targeting inflammatory/fibrotic diseases and cardiovascular diseases is substantial, estimated in billions of dollars. ZyVersa is positioned to address specific segments within these larger markets.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Targeting large unmet medical needs
- Experienced leadership team
Weaknesses
- Early stage of development
- Limited financial resources
- Reliance on clinical trial success
Opportunities
- Potential for breakthrough therapies
- Partnerships and collaborations
- Expansion into new indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- PFE
- NVS
- AMGN
Competitive Landscape
ZyVersa's advantage lies in its novel drug candidates. Disadvantages include limited resources and early stage of development compared to larger competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to early stage of development.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals.
Recent Initiatives: Focus on clinical trials for IC 100 and VAR 200.
Summary
ZyVersa Therapeutics Inc. is an early-stage biopharmaceutical company with novel drug candidates targeting unmet medical needs. The company's success is contingent on successful clinical trials and regulatory approvals. Limited financial resources and competition from established players pose challenges. Opportunities exist for partnerships and expansion into new indications.
Similar Companies
- PFE
- NVS
- AMGN
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and should not be construed as investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ZyVersa Therapeutics Inc.
Exchange NASDAQ | Headquaters Weston, FL, United States | ||
IPO Launch date 2022-12-12 | Co-Founder, Chairman, CEO & President Mr. Stephen C. Glover | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.zyversa.com |
Full time employees - | Website https://www.zyversa.com | ||
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.